Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05126836 · ClinicalTrials.gov registry record · Phase 2

Cilostazol for HFpEF

A Phase 2 study of Heart Failure With Preserved Ejection Fraction, sponsored by University of Minnesota.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target
1
Study location

NCT05126836 is a Phase 2 study of Heart Failure With Preserved Ejection Fraction that has completed, run by University of Minnesota. The registered enrollment target is 25 participants, below the 2,288-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05126836, a Phase 2 study of Heart Failure With Preserved Ejection Fraction, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

Determine if cilostazol improves symptoms and NTproBNP levels (heart failure blood marker) in heart failure with preserved ejection fraction (HFpEF) - a prevalent syndrome without targeted evidence-based treatment. This will be assessed in a prospective 1-month single blinded study with 2 cross-overs n-of-1 study design with placebo and cilostazol

Conditions Studied

Heart Failure With Preserved Ejection Fraction

Interventions

  • DRUG Placebo
  • DRUG Cilostazol 100Mg Tab

Study Locations (1)

Minnesota

  • M Health Fairview - Minneapolis

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2021-09-01
Est. Completion 2022-07-01
Phase Phase 2

Sponsor

University of Minnesota

966 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05126836

The ClinicalTrials.gov registry entry for NCT05126836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,288-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (99% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05126836 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05126836 about?

NCT05126836 is a clinical study titled "Cilostazol for HFpEF". Determine if cilostazol improves symptoms and NTproBNP levels (heart failure blood marker) in heart failure with preserved ejection fraction (HFpEF) - a prevalent syndrome without targeted evidence-based treatment. This will be assessed in a prospective 1-month single blinded study with 2 cross-ove...

What is the current status of trial NCT05126836?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-09-01. Estimated completion is 2022-07-01.

What conditions does trial NCT05126836 study?

This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.

What interventions are being tested in trial NCT05126836?

The interventions under investigation include: Placebo (DRUG), Cilostazol 100Mg Tab (DRUG).

Who is sponsoring clinical trial NCT05126836?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05126836 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Preserved Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure With Preserved Ejection Fraction

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.